Diabetes, Healthy
Conditions
Brief summary
This trial is conducted in Asia. The aim of this clinical trial is to investigate the bioequivalence of repaglinide and metformin combination tablet versus repaglinide and metformin as coadministered tablets after meal. The trial is designed as a three-period, six-sequence, single-dose, crossover pharmacokinetic trial where the trial participant is randomised to one of six possible treatment periods (Williams design). The trial participant will receive one single dose of each trial product in varying order.
Interventions
Combination tablet of repaglinide (1.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
DRUGrepaglinide
Co-administration of metformin 500 mg tablet and repaglinide 2 mg tablet given just prior to a standard normal breakfast
DRUGmetformin
Concomitant administration: Metformin 500 mg tablet and Repaglinide 2 mg tablet
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Willing to sign informed consent before initiating any trial related procedures * BMI: 19.0-25.0 kg/m2 * Fasting plasma glucose: 3.9-6.1 mmol/L * Trial participant is judged to be in good health on the basis of their medical history, physical examination, ECG, and routine laboratory data
Exclusion criteria
* Any clinically significant disease history, in the opinion of the Investigator, of systemic or organ disease * Clinically significant abnormalities on pre-study clinical examination or any laboratory measurements during screening * Any regular use of prescription or nonprescription drugs, including mega-vitamin or herbal supplement regimens that cannot be stopped at least two weeks prior to start of treatment and for the duration of the trial * Currently a smoker (more than one cigarette per day or equivalent) * Use of grapefruit or grapefruit juice within 7 days of trial product dose administration * Blood donation, surgery or trauma with significant blood loss (400 mL) within the last 2 months prior to trial product dose administration * Recent history (within the last 2 years) of drug or alcohol abuse * Known or suspected allergy to trial product or any of the excipients or a history of multiple and/or severe allergies to drugs or foods or of severe anaphylactic reactions * Subject has taken an investigational drug in another clinical trial within the last 4 weeks. * Recent history (within the last 3 month) of nausea, diarrhea or gastrointestinal complaints * History of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose additional risk in administering trial product to the trial participant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC0-t and Cmax (after repaglinide 2.0 mg and metformin 500 mg as co-administered tablets and combination tablet dosing under fed state) | 24hr profile after single dose of trial drug in each treatment period |
Secondary
| Measure | Time frame |
|---|---|
| Repaglinide AUC(0-24 & 0-∞) and Cmax after combination tablet (repaglinide 1.0 mg/metformin 500 mg) during fed state | 24hr profile after single dose of trial drug in each treatment period |
Countries
China
Outcome results
None listed